# Cambrex acquires Halo Pharma from SK Capital for $425 million

Cambrex acquired Halo Pharma, a contract development and manufacturing organization, from SK Capital in Q3 2018 for $425 million.

- Type: Acquisition
- Announced: 2018-10-15
- Where: United States
- Value: $425.0M
- Status: completed
- Products: contract development and manufacturing
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [SK Capital](https://endata.com/companies/5414.md) (partner)
- [Cambrex](https://endata.com/companies/27131.md) (acquirer)
- [Halo Pharma](https://endata.com/companies/34875.md) (target)

## Sources

- [everchem.com](https://everchem.com/q3-ma-update/), 2018-10-15: "Chemical Deal Results | Seller | Buyer | Business | Date |"
- [everchem.com](https://everchem.com/q3-ma-update-2/), 2018-10-15: "Chemical Deal Results | Seller | Buyer | Business | Date |"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.